SK Biopharm earnings on track, Phase 3 resumption of Ojjaara in focus [Why Bio]
Predicted impact: Low
Earnings described as on track with no surprise; trial resumption is vague timing.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.